Bionime Corp Net Assets
Bionime Corp net assets. Based on the latest financial reports, Bionime Corp (4737) has net assets worth NT$2.21 Billion TWD (≈ $69.71 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$5.65 Billion ≈ $178.16 Million USD) and total liabilities (NT$3.44 Billion ≈ $108.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Bionime Corp equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.21 Billion |
| % of Total Assets | 39.13% |
| Annual Growth Rate | 6.5% |
| 5-Year Change | -15.44% |
| 10-Year Change | -32.13% |
| Growth Volatility | 26.6 |
Net Assets of Bionime Corp (2009–2025)
Net assets of Bionime Corp from 2009 to 2025. This chart illustrates how Bionime Corp's net assets have evolved over time, based on quarterly financial data. See 4737 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Bionime Corp (2009–2025)
The table below shows the annual net assets of Bionime Corp from 2009 to 2025. For live market cap and overall valuation, see market cap of Bionime Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.76 Billion ≈ $55.31 Million |
-7.06% |
| 2024-12-31 | NT$1.89 Billion ≈ $59.51 Million |
-5.23% |
| 2023-12-31 | NT$1.99 Billion ≈ $62.80 Million |
-4.20% |
| 2022-12-31 | NT$2.08 Billion ≈ $65.55 Million |
+0.21% |
| 2021-12-31 | NT$2.08 Billion ≈ $65.41 Million |
+0.26% |
| 2020-12-31 | NT$2.07 Billion ≈ $65.24 Million |
+1.17% |
| 2019-12-31 | NT$2.05 Billion ≈ $64.49 Million |
+2.70% |
| 2018-12-31 | NT$1.99 Billion ≈ $62.79 Million |
-4.07% |
| 2017-12-31 | NT$2.08 Billion ≈ $65.46 Million |
-19.68% |
| 2016-12-31 | NT$2.59 Billion ≈ $81.50 Million |
+1.77% |
| 2015-12-31 | NT$2.54 Billion ≈ $80.08 Million |
+88.68% |
| 2014-12-31 | NT$1.35 Billion ≈ $42.44 Million |
+25.82% |
| 2013-12-31 | NT$1.07 Billion ≈ $33.73 Million |
+6.96% |
| 2012-12-31 | NT$1.00 Billion ≈ $31.54 Million |
-7.75% |
| 2011-12-31 | NT$1.09 Billion ≈ $34.19 Million |
+6.75% |
| 2010-12-31 | NT$1.02 Billion ≈ $32.02 Million |
+58.59% |
| 2009-12-31 | NT$640.89 Million ≈ $20.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bionime Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 223.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Bionime Corp Net Assets Breakdown (December 2025)
Bionime Corp net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$673.32 Million | 38.58% |
| Other Components | NT$1.24 Billion | 71.00% |
| Total Equity | NT$1.75 Billion | 100.00% |
Bionime Corp Competitors by Market Cap
The table below lists competitors of Bionime Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pro-Dex Inc
NASDAQ:PDEX
|
$159.74 Million |
|
Dividend 15 Split Corp II
TO:DF
|
$159.78 Million |
|
UmweltBank AG
XETRA:UBK
|
$159.79 Million |
|
DCX Systems Limited
NSE:DCXINDIA
|
$159.80 Million |
|
Unisys Corporation
NYSE:UIS
|
$159.73 Million |
|
Michman Basad Ltd
TA:MCMN
|
$159.67 Million |
|
Theta Gold Mines Ltd
AU:TGM
|
$159.60 Million |
|
Phuoc Hoa Rubber JSC
VN:PHR
|
$159.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bionime Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,879,978,000 to 1,745,406,000, a change of -134,572,000 (-7.2%).
- Net loss of 180,277,000 reduced equity.
- New share issuances of 5,377,000 increased equity.
- Other factors increased equity by 40,328,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-180.28 Million | -10.33% |
| Share Issuances | NT$5.38 Million | +0.31% |
| Other Changes | NT$40.33 Million | +2.31% |
| Total Change | NT$- | -7.16% |
Book Value vs Market Value Analysis
This analysis compares Bionime Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.52x to 2.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$14.51 | NT$65.60 | x |
| 2010-12-31 | NT$24.86 | NT$65.60 | x |
| 2011-12-31 | NT$22.02 | NT$65.60 | x |
| 2012-12-31 | NT$20.34 | NT$65.60 | x |
| 2013-12-31 | NT$22.10 | NT$65.60 | x |
| 2014-12-31 | NT$27.58 | NT$65.60 | x |
| 2015-12-31 | NT$44.51 | NT$65.60 | x |
| 2016-12-31 | NT$36.84 | NT$65.60 | x |
| 2017-12-31 | NT$31.49 | NT$65.60 | x |
| 2018-12-31 | NT$31.18 | NT$65.60 | x |
| 2019-12-31 | NT$31.62 | NT$65.60 | x |
| 2020-12-31 | NT$31.13 | NT$65.60 | x |
| 2021-12-31 | NT$30.96 | NT$65.60 | x |
| 2022-12-31 | NT$30.70 | NT$65.60 | x |
| 2023-12-31 | NT$29.50 | NT$65.60 | x |
| 2024-12-31 | NT$28.06 | NT$65.60 | x |
| 2025-12-31 | NT$25.70 | NT$65.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bionime Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.81%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 3.27x
- Recent ROE (-10.33%) is below the historical average (5.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 21.10% | 14.42% | 1.05x | 1.39x | NT$71.15 Million |
| 2010 | 13.39% | 11.23% | 0.94x | 1.27x | NT$34.41 Million |
| 2011 | 16.51% | 12.13% | 0.52x | 2.63x | NT$70.60 Million |
| 2012 | 3.41% | 2.38% | 0.40x | 3.63x | NT$-65.95 Million |
| 2013 | 8.40% | 5.76% | 0.35x | 4.23x | NT$-17.14 Million |
| 2014 | 4.03% | 3.56% | 0.33x | 3.46x | NT$-80.41 Million |
| 2015 | 3.89% | 6.14% | 0.35x | 1.80x | NT$-155.40 Million |
| 2016 | 6.91% | 10.27% | 0.37x | 1.80x | NT$-79.89 Million |
| 2017 | 7.20% | 8.22% | 0.42x | 2.11x | NT$-58.15 Million |
| 2018 | 6.43% | 6.38% | 0.44x | 2.30x | NT$-71.09 Million |
| 2019 | 5.20% | 4.89% | 0.49x | 2.16x | NT$-98.00 Million |
| 2020 | 3.02% | 3.74% | 0.37x | 2.17x | NT$-144.13 Million |
| 2021 | 4.22% | 4.73% | 0.41x | 2.21x | NT$-119.52 Million |
| 2022 | 4.39% | 4.12% | 0.44x | 2.40x | NT$-116.22 Million |
| 2023 | 0.31% | 0.35% | 0.33x | 2.67x | NT$-192.39 Million |
| 2024 | -6.77% | -6.58% | 0.33x | 3.08x | NT$-315.21 Million |
| 2025 | -10.33% | -9.81% | 0.32x | 3.27x | NT$-354.82 Million |
Industry Comparison
This section compares Bionime Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,801,079,778
- Average return on equity (ROE) among peers: 12.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bionime Corp (4737) | NT$2.21 Billion | 21.10% | 1.56x | $159.73 Million |
| St.Shine Optical Co Ltd (1565) | $6.14 Billion | 8.90% | 0.26x | $143.27 Million |
| Maxigen Biotech Inc (1783) | $1.38 Billion | 13.83% | 0.15x | $99.19 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $108.90 Million |
| Bioteque (4107) | $1.24 Billion | 13.88% | 0.36x | $228.15 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $53.72 Million |
| BenQ Medical Technology (4116) | $1.12 Billion | 5.55% | 0.61x | $62.06 Million |
| Pacific Hospital Supply Co Ltd (4126) | $1.35 Billion | 25.50% | 0.22x | $172.69 Million |
| Vizionfocus Inc. (4771) | $1.81 Billion | 12.94% | 0.60x | $388.43 Million |
| Formosa Optical Technology Co Ltd (5312) | $935.17 Million | 16.96% | 0.64x | $166.70 Million |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTE… Read more